← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	1,523	+65	+4%	$97.8B
2	2 Danaher DHR $158B	1,376	+73	+6%	$75.9B
3	3 Novartis NVS $279B	1,134	+46	+4%	$26.2B
4	4 Illumina ILMN $41B	877	+32	+4%	$41.7B
5	5 Agilent Technologies A $49.1B	732	+38	+5%	$22.2B
6	6 Regeneron Pharmaceuticals REGN $80.1B	719	+48	+7%	$30.4B
7	7 Revvity RVTY $17B	420	+38	+10%	$10.3B
8	8 Charles River Laboratories CRL $14.4B	409	+2	+0.5%	$6.79B
9	9 Ionis Pharmaceuticals IONS $7.1B	393	+63	+19%	$9.53B
10	10 Sarepta Therapeutics SRPT $1.78B	372	+36	+11%	$8.48B
11	11 Alnylam Pharmaceuticals ALNY $30B	291	+7	+2%	$9.06B
12	12 DELISTED bluebird bio BLUE	288	+37	+15%	$9.81B
13	13 DELISTED CATALENT, INC. CTLT	283	+16	+6%	$6.02B
14	14 Myriad Genetics MYGN $397M	262	-2	-0.8%	$2.62B
15	15 Qiagen QGEN $9.41B	262	+10	+4%	$5.86B
16	16 Bruker BRKR $8.47B	249	+20	+9%	$4.08B
17	17 Azenta AZTA $1.63B	242	+14	+6%	$2.22B
18	18 Regenxbio RGNX $454M	211	+28	+15%	$1.73B
19	19 Editas Medicine EDIT $349M	201	+7	+4%	$918M
20	20 DELISTED SANGAMO THERAPEUTICS INC SGMO	187	-10	-5%	$631M
21	NVTA 21 DELISTED Invitae Corporation NVTA	183	+41	+29%	$1.66B
22	22 CareDx CDNA $3.35B	182	+34	+23%	$1.18B
23	23 Ultragenyx Pharmaceutical RARE $1.47B	177	+12	+7%	$4.05B
24	24 Arrowhead Research ARWR $8.25B	175	+17	+11%	$1.09B
25	25 PTC Therapeutics PTCT $4.98B	174	+10	+6%	$2.21B